CybeRelease: (OTC: AMZB) Gets Patent Approval for Unique HIV Treatment

(CybeRelease, September 6, 2006) - Lake Harmony, PA - Amazon Biotech, Inc. (OTC BB: AMZB) (Frankfurt:B2DF.F) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon’s application for patent protection of its investigative drug named AMZ0026 has been approved.

AMZ0026, a therapeutic herbal composition, is Amazon Biotech’s primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.

Dr. Mechael Kanovsky, President of Amazon Biotech, stated, “We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value.”

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

To read the complete release, go to http://biz.yahoo.com/iw/060905/0159946.html

For a Free Newsletter and more information, go to http://www.OTCReporter.com

CybeRelease Gainers are Sonus Networks, Inc. (Nasdaq: SONS), Netflix, Inc. (Nasdaq: NFLX), DayStar Technologies, Inc. (Nasdaq: DSTI), New Frontier Media, Inc. (Nasdaq: NOOF), Rambus, Inc. (Nasdaq: RMBS), ASML Holding N.V. (Nasdaq: ASML), ABIOMED, Inc. (Nasdaq: ABMD) and Stratex Networks Inc. (Nasdaq: STXN).

CybeRelease Decliners are Carrier Access Corporation (Nasdaq: CACS), Finisar Corporation (Nasdaq: FNSR), priceline.com Incorporated (Nasdaq: PCLN), Anglo American plc (Nasdaq: AAUK), Adolor Corporation (Nasdaq: ADLR), Business Objects S.A. (Nasdaq: BOBJ), SanDisk Corporation (Nasdaq: SNDK) and Sirius Satellite Radio Inc. (Nasdaq: SIRI).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact:
C. P. Barry
Company: CybeRelease
Phone: 1.888.478.7669
Source: CybeRelease.com

Contact Information

C. P. Barry

Media Contact

CybeRelease.com

Contact via E-mail